title: Moderators of effects of motivational enhancements to cognitive behavioral therapy.
abstract: Patient treatment matching hypotheses were tested for substance users randomly assigned to a group cognitive behavioral therapy (CBT; n= 114) or a group motivational intervention (GMI; n= 116). Treatment was scheduled twice weekly for 10 weeks. Using a patient attribute by treatment interaction design with a 15-week follow-up, the study predicted that alexithymia, antisocial personality disorder (ASPD), and network support for alcohol and drug use would be associated with less substance use for CBT subjects and that hostility and lower treatment motivation would be associated with less substance use for GMI subjects. Three of the hypothesized moderators were empirically supported: alexithymia, network support for alcohol, and ASPD. Results indicate the use of assessing specific patient attributes to better inform treatment recommendations.
authors.affiliation: Institute for Treatment and Services Research, National Development and Research Institutes, Inc, New York, New York 10048, USA. rosenblum@ndri.org
authors.forename: Andrew
authors.initials: A
authors.lastname: Rosenblum
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Foote
authors.forename: Charles
authors.initials: C
authors.lastname: Cleland
authors.forename: Stephen
authors.initials: S
authors.lastname: Magura
authors.forename: Daneyal
authors.initials: D
authors.lastname: Mahmood
authors.forename: Nicole
authors.initials: N
authors.lastname: Kosanke
mesh_terms: D000328:Adult; D000342:Affective Symptoms / Q000175:diagnosis / Q000453:epidemiology; D000987:Antisocial Personality Disorder / Q000453:epidemiology; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006197:Hair / Q000737:chemistry; D006791:Hostility; D006801:Humans; D008297:Male; D009042:Motivation; D011863:Radioimmunoassay; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*